

19 October 2023

Our Ref: RFI 53570

Dear

**Freedom of Information Act 2000
Information in Relation to Treatment of Breast Cancer**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above which you requested on 18 September 2023. Please accept my apologies for the delay in responding to your request, thank you for your understanding and forbearance of this matter.

A response to each of the questions raised has been provided by the Surgery, Elective Care, Maternity & Paediatrics Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Caroline Degans
Information Governance Officer

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet.

A1. Please see Table 1 for the number of patients treated with the following medicines between the start of June 2023 and end of August 2023.

Table 1

Name of Medicine	Number of Patients Treated
Abemaciclib (Verzenios)	5
Alpelisib (Piqray)	Nil
Fulvestrant (fulvestrant or Faslodex)	56
Palbociclib (Ibrance)	40
Ribociclib (Kisqali)	17

Q2. How many patients received Abemaciclib (Verzenios) for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet.

A2. There were no patients who received Abemaciclib (Verzenios) for early breast cancer in the 3 months between start of June 2023 and end of August 2023.

Q3. How many patients received Abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet.

A3. There were 5 patients who received Abemaciclib (Verzenios) as adjuvant treatment for early breast cancer in the 3 months between the start of June 2023 and end of August 2023.

Q4. How many patients received Abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet.

- A4. Please see Table 2 for the number of patients who received Abemaciclib (Verzenios) with the following treatment intent between the start of June 2023 and end of August 2023.

Table 2

Treatment Intent	Number of Patients Treated
Curative	5
Palliative	Nil
Not known / stated	Nil

- Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?**

Please provide data for the latest 3-month period, if Jun to Aug is not available yet.

- A5. Please see Table 3 for the number of patients treated with the following medicines in combination between the start of June 2023 and end of August 2023.

Table 3

Name of Combination or Monotherapy	Number of patients Treated
Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	Nil
Abemaciclib (Verzenios) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	5
Abemaciclib (Verzenios) + tamoxifen	Nil
Abemaciclib monotherapy	Nil
Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	Nil
Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	4
Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	36
Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	Nil
Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	17